FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Karoly Szepeshazi

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Physiology

Cell Divisions

Procedures

Disorders

Prostatic Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Ferenc Rick; Andrew Abi-Chaker; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Arumugam R Jayakumar; AWTAR KRISHAN; Roberto Perez; Nagarajarao Shamaladevi; Luca Szalontay; Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Karoly Szepeshazi; Irving Vidaurre; Norman Block; Gabor Halmos; Ferenc Rick; Andrew V Schally; Luca Szalontay
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally; Luca Szalontay; Daniel Benten; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Gunhild Keller; Ferenc Rick
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Karoly Szepeshazi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Ferenc Rick; Andrew Abi-Chaker; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Arumugam R Jayakumar; AWTAR KRISHAN; Roberto Perez; Nagarajarao Shamaladevi; Luca Szalontay; Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(7):2617-22.
2012: Karoly Szepeshazi; Irving Vidaurre; Norman Block; Gabor Halmos; Ferenc Rick; Andrew V Schally; Luca Szalontay
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Anti-cancer drugs 2012;23(9):906-13.
2012: Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally; Luca Szalontay; Daniel Benten; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Gunhild Keller; Ferenc Rick
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Oncotarget 2012;3(7):686-99.
2012: Ferenc Rick; Andrew V Schally; Luca Szalontay; Karoly Szepeshazi; Irving Vidaurre; Marta Zarandi; Norman Block; Magdolna Kovacs; Mehrdad Nadji; Zoltan Rekasi
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
The Journal of urology 2012;187(4):1498-504.
2012: Ferenc Rick; Andrew V Schally; Luca Szalontay; Karoly Szepeshazi; Marta Zarandi; Norman Block; Stefan Buchholz; Florian Hohla; Mehrdad Nadji; Stephan Seitz
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(5):1655-60.
2011: Ferenc Rick; Andrew V Schally; Norman Block; Mehrdad Nadji; Karoly Szepeshazi; Marta Zarandi; Irving Vidaurre; Roberto Perez; Gabor Halmos; Luca Szalontay
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(9):3755-60.
2009: Andrea Treszl; Andrew V Schally; Stephan Seitz; Luca Szalontay; Ferenc Rick; Karoly Szepeshazi; Gabor Halmos
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Peptides 2009;30(9):1643-50.
2009: Stephan Seitz; Andrew V Schally; Andrea Treszl; Andrea Papadia; Ferenc Rick; Luca Szalontay; Karoly Szepeshazi; Olaf Ortmann; Gabor Halmos; Florian Hohla; Stefan Buchholz
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-cancer drugs 2009;20(7):553-8.
2008: Karoly Szepeshazi; Andrew V Schally; Andrea Treszl; Stephan Seitz; Gabor Halmos
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Anti-cancer drugs 2008;19(4):349-58.
2007: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
International journal of oncology 2007;30(6):1485-92.
2006: Florian Hohla; Andrew V Schally; Karoly Szepeshazi; Jozsef Varga; Stefan Buchholz; Frank Köster; Elmar Heinrich; Gabor Halmos; Ferenc Rick; Chandrika Kannadka; Christian Datz; Celia A Kanashiro
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14513-8.
2006: Anton Stangelberger; Andrew V Schally; Attila Nagy; Karoly Szepeshazi; Celia A Kanashiro; Gabor Halmos
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
The Prostate 2006;66(2):200-10.
2006: Anton Stangelberger; Andrew V Schally; Markus Letsch; Karoly Szepeshazi; Attila Nagy; Gabor Halmos; Celia A Kanashiro; Eva Corey; Robert L Vessella
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
International journal of cancer. Journal international du cancer 2006;118(1):222-9.
2005: Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(48):17424-9.
2005: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Gabor Halmos
Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas 2005;31(3):275-82.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Marta Zarandi; Karoly Szepeshazi; Patricia Armatis; Gabor Halmos
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):49-57.
2004: Andrew V Schally; Karoly Szepeshazi; Attila Nagy; Ana Maria Comaru-Schally; Gabor Halmos
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cellular and molecular life sciences : CMLS 2004;61(9):1042-68.
2004: Markus Letsch; Andrew V Schally; Karoly Szepeshazi; Gabor Halmos; Attilla Nagy
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
The Journal of urology 2004;171(2 Pt 1):911-5.
2004: Ana M Bajo; Andrew V Schally; Kate Groot; Karoly Szepeshazi
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
British journal of cancer 2004;90(1):245-52.
2003: Zoltan Szereday; Andrew V Schally; Jozsef Varga; Celia A Kanashiro; Francine Hebert; Patricia Armatis; Kate Groot; Karoly Szepeshazi; Gabor Halmos; Rebeca Busto
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer research 2003;63(22):7913-9.
2003: Markus Letsch; Andrew V Schally; Karoly Szepeshazi; Gabor Halmos; Attila Nagy
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4505-13.
2003: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Brady W Wagner; Ana M Bajo; Gabor Halmos
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer 2003;98(7):1401-10.
2003: Zoltan Szereday; Andrew V Schally; Karoly Szepeshazi; Ana M Bajo; Francine Hebert; Gabor Halmos; Attila Nagy
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
International journal of oncology 2003;22(5):1141-6.
2002: Rebeca Busto; Andrew V Schally; Jozsef Varga; M Olga Garcia-Fernandez; Kate Groot; Patricia Armatis; Karoly Szepeshazi
The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11866-71.
2002: Zoltan Szereday; Andrew V Schally; Attila Nagy; Artur Plonowski; Ana M Bajo; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
British journal of cancer 2002;86(8):1322-7.
2002: Ana M Bajo; Andrew V Schally; Magdalena Krupa; Francine Hebert; Kate Groot; Karoly Szepeshazi
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(6):3836-41.
2002: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Patricia Armatis; Francine Hebert; Baodong Sun; Anita Feil; Hippokratis Kiaris; Attila Nagy
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research 2002;62(3):781-8.
2001: Andrew V Schally; Ana Maria Comaru-Schally; Attila Nagy; Magdolna Kovacs; Karoly Szepeshazi; Artur Plonowski; Jozsef Varga; Gabor Halmos
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Karoly Szepeshazi; Andrew V Schally; Patricia Armatis; Kate Groot; Francine Hebert; A Feil; Jozsef Varga; Gabor Halmos
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology 2001;142(10):4371-8.
2001: Ioulia Chatzistamou; Andrew V Schally; Karoly Szepeshazi; Kate Groot; Francine Hebert; Jose M Arencibia
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Cancer letters 2001;171(1):37-45.
2001: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Baodong Sun; Francine Hebert; Balazs Csernus; Attila Nagy
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2854-61.
2001: Jose M Arencibia; Andrew V Schally; Magdalena Krupa; Ana M Bajo; Attila Nagy; Karoly Szepeshazi; Artur Plonowski
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
International journal of oncology 2001;19(3):571-7.
2001: Hippokratis Kiaris; Andrew V Schally; Attila Nagy; Karoly Szepeshazi; Francine Hebert; Gabor Halmos
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
European journal of cancer (Oxford, England : 1990) 2001;37(5):620-8.
2000: L Chatzistamou; Andrew V Schally; Attila Nagy; Patricia Armatis; Karoly Szepeshazi; Gabor Halmos
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4158-65.
2000: Ioulia Chatzistamou; Andrew V Schally; Baodong Sun; Patricia Armatis; Karoly Szepeshazi
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
British journal of cancer 2000;83(7):906-13.
2000: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Patricia Armatis; Gabor Halmos; F Herbert; Béla Szende; Jozsef Varga; Marta Zarandi
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
British journal of cancer 2000;82(10):1724-31.
2000: Hippokratis Kiaris; Andrew V Schally; Attila Nagy; Baodong Sun; Karoly Szepeshazi; Gabor Halmos
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):709-17.
2000: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Patricia Armatis; Francine Hebert; Gabor Halmos
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(1):128-36.
1999: Hippokratis Kiaris; Andrew V Schally; Attila Nagy; Baodong Sun; Patricia Armatis; Karoly Szepeshazi
Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
British journal of cancer 1999;81(6):966-71.
1999: Karoly Szepeshazi; Andrew V Schally; Attila Nagy
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Breast cancer research and treatment 1999;56(3):267-76.
1999: M Miyazaki; Andrew V Schally; Attila Nagy; N Lamharzi; Gabor Halmos; Karoly Szepeshazi; Patricia Armatis
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
American journal of obstetrics and gynecology 1999;180(5):1095-103.
1999: Artur Plonowski; Andrew V Schally; Attila Nagy; Baodong Sun; Karoly Szepeshazi
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Cancer research 1999;59(8):1947-53.
1998: M Miyazaki; N Lamharzi; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Renzhi Cai
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
European journal of cancer (Oxford, England : 1990) 1998;34(5):710-7.
1998: Andreas Jungwirth; Andrew V Schally; Gabor Halmos; Kate Groot; Karoly Szepeshazi; Jacek Pinski; Patricia Armatis
Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Cancer 1998;82(5):909-17.
1997: M Miyazaki; Attila Nagy; Andrew V Schally; N Lamharzi; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Patricia Armatis
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute 1997;89(23):1803-9.
1997: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Gabor Halmos; Kate Groot
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anti-cancer drugs 1997;8(10):974-87.
1997: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; N Lamharzi; Kate Groot; Judit E Horvath
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(20):10913-8.
1997: Andreas Jungwirth; G Galvan; Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Renzhi Cai; Kate Groot; Andrew V Schally
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
The Prostate 1997;32(3):164-72.
1997: Andreas Jungwirth; Jacek Pinski; G Galvan; Gabor Halmos; Karoly Szepeshazi; Renzhi Cai; Kate Groot; M Vadillo-Buenfil; Andrew V Schally
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1141-8.
1997: Attila Nagy; Patricia Armatis; Renzhi Cai; Karoly Szepeshazi; Gabor Halmos; Andrew V Schally
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(2):652-6.
1996: Attila Nagy; Andrew V Schally; Patricia Armatis; Karoly Szepeshazi; Gabor Halmos; Magdolna Kovacs; Marta Zarandi; Kate Groot; M Miyazaki; Andreas Jungwirth; J Horvath
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7269-73.
1996: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice.
International journal of cancer. Journal international du cancer 1996;65(6):870-4.
1996: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; B Szoke; Kate Groot; Attila Nagy
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast cancer research and treatment 1996;40(2):129-39.
1995: Jacek Pinski; Andrew V Schally; Kate Groot; Gabor Halmos; Karoly Szepeshazi; Marta Zarandi; Patricia Armatis
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
Journal of the National Cancer Institute 1995;87(23):1787-94.
1994: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Cancer research 1994;54(22):5895-901.
1994: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot; K O'Byrne; Renzhi Cai
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
British journal of cancer 1994;70(5):886-92.
1994: T Yano; Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Andrew V Schally
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(15):7090-4.
1994: Jacek Pinski; Gabor Halmos; T Yano; Karoly Szepeshazi; Y Qin; T Ertl; Andrew V Schally
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
International journal of cancer. Journal international du cancer 1994;57(4):574-80.
1994: T Yano; Jacek Pinski; Karoly Szepeshazi; Gabor Halmos; S Radulovic; K Groot; Andrew V Schally
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Cancer 1994;73(4):1229-38.
1994: Sinisa Radulovic; Andrew V Schally; H Reile; Gabor Halmos; Karoly Szepeshazi; Kate Groot; S Milovanovic; G Miller; T Yano
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
Acta oncologica (Stockholm, Sweden) 1994;33(6):693-701.
1994: Béla Szende; A Csikós; Karoly Szepeshazi; Jimmy Neill; J J Mulchahey; Gabor Halmos; Károly Lapis; Andrew V Schally
The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
Receptor 1994;4(4):201-7.
1994: Y Shirahige; Renzhi Cai; Karoly Szepeshazi; Gabor Halmos; Jacek Pinski; Kate Groot; Andrew V Schally
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1994;48(10):465-72.
1994: K J O'Byrne; Gabor Halmos; Jacek Pinski; Kate Groot; Karoly Szepeshazi; Andrew V Schally; D N Carney
Somatostatin receptor expression in lung cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1682-7.
1993: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi
Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
International journal of cancer. Journal international du cancer 1993;55(6):963-7.
1993: Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Andrew V Schally
Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Cancer 1993;72(11):3263-70.
1993: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Gabor Halmos
Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
International journal of cancer. Journal international du cancer 1993;54(2):282-9.
1993: Jacek Pinski; T Yano; Karoly Szepeshazi; K Groot; Andrew V Schally
Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).
Journal of andrology 1993;14(3):164-9.
1993: S R Milovanovic; E Monje; Karoly Szepeshazi; Sinisa Radulovic; Andrew V Schally
Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Journal of cancer research and clinical oncology 1993;119(5):273-8.
1993: Jacek Pinski; Andrew V Schally; T Yano; Karoly Szepeshazi; Gabor Halmos; Kate Groot; A M Comaru-Schally; Sinisa Radulovic; Attila Nagy
Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
The Prostate 1993;23(2):165-78.
1992: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Kate Groot; Sinisa Radulovic
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Journal of the National Cancer Institute 1992;84(24):1915-22.
1992: T W Redding; Andrew V Schally; Sinisa Radulovic; S Milovanovic; Karoly Szepeshazi; John T Isaacs
Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Cancer research 1992;52(9):2538-44.
1992: Karoly Szepeshazi; Andrew V Schally; A Juhasz; Attila Nagy; T Janaky
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
Anti-cancer drugs 1992;3(2):109-16.
1992: T Yano; E Korkut; Jacek Pinski; Karoly Szepeshazi; S Milovanovic; Kate Groot; Robert Clarke; A M Comaru-Schally; Andrew V Schally
Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Breast cancer research and treatment 1992;21(1):35-45.
1992: Karoly Szepeshazi; S Milovanovic; Károly Lapis; Kate Groot; Andrew V Schally
Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Breast cancer research and treatment 1992;21(3):181-92.
1992: T Yano; Jacek Pinski; Karoly Szepeshazi; S R Milovanovic; Kate Groot; Andrew V Schally
Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
The Prostate 1992;20(4):297-310.
1991: Karoly Szepeshazi; Andrew V Schally; Renzhi Cai; Sinisa Radulovic; S Milovanovic; B Szoke
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Cancer research 1991;51(21):5980-6.
1991: Karoly Szepeshazi; Károly Lapis; Andrew V Schally
Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
International journal of cancer. Journal international du cancer 1991;49(2):260-6.
1991: L Bokser; G Srkalovic; Karoly Szepeshazi; Andrew V Schally
Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
Neuroendocrinology 1991;54(2):136-45.
1991: Béla Szende; G Srkalovic; Jozsef Timar; J J Mulchahey; Jimmy Neill; Károly Lapis; A Csikos; Karoly Szepeshazi; Andrew V Schally
Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(10):4153-6.
1991: Karoly Szepeshazi; E Korkut; Andrew V Schally
Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone.
The American journal of pathology 1991;138(5):1273-7.
1991: Karoly Szepeshazi; E Korkut; Béla Szende; Károly Lapis; Andrew V Schally
Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
The Prostate 1991;18(3):255-70.
1990: Andrew V Schally; G Srkalovic; Béla Szende; T W Redding; T Janaky; A Juhasz; E Korkut; Renzhi Cai; Karoly Szepeshazi; Sinisa Radulovic
Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1061-7.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.